WEST FRONT STRATEGIES LLC for FRESENIUS KABI USA LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to patent policy and reform, including terminal disclaimers; FDA/PTO Coordination, including Interagency Patent Coordination and Improvement Act of 2023 (S.79); Prescription Pricing for the People Act of 2023 (S.113); Preserve Access to Affordable Generics and Biosimilars Act (S.142); Affordable Prescriptions for Patients Act of 2023 (S.150).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
| SHIMON STEIN | — |
Medicare/Medicaid MMM
Formulary placement of generics and biosimilar biological products in Part D; issues related to access to biosimilar biological products in Medicare Part B; issues related to rebate walls.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
Pharmacy PHA
Issues related to drug pricing; issues related to Biosimilars; issues related to competition.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BUKI | — |
| ASHLEY DAVIS | — |
| CRAIG KALKUT | — |
| MALLOY MCDANIEL | — |
| KRISTI REMINGTON | — |
| SHIMON STEIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.